Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response

BACKGROUND: Despite the proven efficacy of vedolizumab (VDZ) for ulcerative colitis (UC) and Crohn’s disease (CD), suboptimal response is commonly encountered. However, data regarding the effectiveness of dose intensification (by interval shortening) to achieve response are limited. OBJECTIVES: We e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Frontline Gastroenterol
Autors principals: Samaan, Mark A, Birdi, Siddharth, Morales, Maria Sierra, Honap, Sailish, Tamilarasan, Aravind Gokul, Cunningham, Georgina, Koumoutsos, Ioannis, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H C, Sanderson, Jeremy, Irving, Peter M
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019
Matèries:
Colorectal
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7223295/
https://ncbi.nlm.nih.gov/pubmed/32419909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/flgastro-2019-101259
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars